Scott Moonly has been hired as head of corporate venture capital at WL Gore & Associates, the US fluoropolymer-derived product manufacturer best known for its waterproof fabrics, Gore-Tex.
In this role, Moonly will oversee the company’s healthcare fund, sustainability fund and internal ventures.
WL Gore & Associates last disclosed an investment in insulin delivery system developer PhysioLogic Devices in 2019. It scored an exit when diabetes regenerative medicine developer ViaCyte was acquired by small molecule drug supplier Vertex Pharmaceuticals for $320m in 2022.
Before joining WL Gore & Associates, Moonly was a partner between March and August 2023 at Aliath Bioventures, the life sciences venture investor and a subsidiary of investment firm AltamarCAM.
Previously, Moonly was a principal at Johnson & Johnson Innovation – JJDC, the strategic venture capital arm of pharmaceutical group Johnson & Johnson Innovation, for nearly five years from 2007. He then spent eight and a half years at medical equipment producer USGI Medical, first as president and CEO before an executive chairman role.